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Background. The group Ameningococcal vaccine (PsA-TT) clinical development plan included clinical trials in
India and in the West African region between 2005 and 2013. During this period, the Meningitis Vaccine Project
(MVP) accumulated substantial experience in the ethical conduct of research to the highest standards.
Methods. Because of the public–private nature of the sponsorship of these trials and the extensive international
collaboration with partners from a diverse setting of countries, the ethical review process was complex and required
strategic, timely, and attentive communication to ensure the smooth review and approval for the clinical studies.
Investigators and their site teams fostered strong community relationships prior to, during, and after the studies
to ensure the involvement and the ownership of the research by the participating populations. As the clinical
work proceeded, investigators and sponsors responded to speciﬁc questions of informed consent, pregnancy testing,
healthcare, disease prevention, and posttrial access.
Results. Key factors that led to success included (1) constant dialogue betweenpartners to explore and answerall ethical
questions; (2) alertness and preparedness for emerging ethical questions during the research and in the context of evolving
international ethics standards; and (3) care to assure that approaches were acceptable in the diverse community contexts.
Conclusions. Many of the ethical issues encountered during the PsA-TT clinical development are familiar to
groups conducting ﬁeld trials in different cultural settings. The successful approaches used by the MVP clinical
team offer useful examples of how these problems were resolved.
Clinical Trials Registration. ISRCTN17662153 (PsA-TT-001); ISRTCN78147026 (PsA-TT-002);
ISRCTN87739946 (PsA-TT-003); ISRCTN46335400 (PsA-TT-003a); ISRCTN82484612 (PsA-TT-004); CTRI/2009/
091/000368 (PsA-TT-005); PACTRATMR2010030001913177 (PsA-TT-006); PACTR201110000328305 (PsA-TT-007).
Keywords. informed consent; ethics; subject protection; ethics committees; developing countries.
Between 2005 and 2013, the Meningitis Vaccine Project
(MVP) and partners conducted 9 clinical studies to
evaluate a new group A meningococcal conjugate vac-
cine (PsA-TT), manufactured at the Serum Institute of
India, Ltd, in Pune, India. The clinical studies enrolled
and followed >11 000 participants at 8 clinical trial sites
in The Gambia, Ghana, India, Mali, and Senegal. All
MVP clinical studies were conducted following the
aFormerly with Medical Research Council Unit, The Gambia.
bPresent afﬁliation: independent consultant.
cFormerly director of the Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Correspondence: Lionel Martellet, MA, Meningitis Vaccine Project, PATH, Gene-
va, Switzerland (lmartellet@path.org).
Clinical Infectious Diseases® 2015;61(S5):S422–7
© The Author 2015. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in
any medium, provided the original work is properly cited.
DOI: 10.1093/cid/civ598
S422 • CID 2015:61 (Suppl 5) • Martellet et al
Declaration of Helsinki, the International Conference of Har-
monisation–Good Clinical Practice guidelines (ICH-GCP),
and in accordance with other international, national, and
local guidelines as applicable [1–4]. Because of the scope and
location of this clinical program, MVP and its partners have ac-
cumulated valuable experience in resolving ethical questions that
arose during the preparation and conduct of the studies. This ar-
ticle highlights the ethical review process, community permission,
informed consent, and other ethical issues that were encountered
during the clinical program.
ETHICAL REVIEWS
Responsible Ethics Committees for MVP Clinical Studies
Because MVP was a partnership between the World Health Or-
ganization (WHO) and PATH, all MVP clinical trial proposals
were reviewed by the WHO Research Ethics Review Committee,
Switzerland (WHO-ERC), and by the PATH Research Ethics
Committee (PATH-REC) or the Western Institutional Review
Board (WIRB), an independent ethics committee (EC) based
in the United States. In addition, for all clinical sites, approvals
were obtained from national or institutional ECs and the na-
tional regulatory authorities (NRAs) of respective countries.
Figure 1 provides an overview of the ethical landscape for the
PsA-TT clinical trials. Every submission and communication
with the ECs was handled in close collaboration with the spon-
sor study representative and the principal investigator. It was
important to speak with one voice to the ECs to ensure that
any recommended changes or issues raised by an EC would
also be communicated to other ECs. The sponsors and the in-
vestigators were key to making this happen through joint corre-
spondence and teleconferences (designated groups are listed in
Figure 1). The end result was that we routinely provided feed-
back not only to local ECs but, in a timely fashion, to WHO-
ERC, PATH-REC, and WIRB.
MVP Ethical and Regulatory Submission Strategy
Because of the number of ethics committees involved, a proper
sequence of submissions and reviews was essential; the plan was
developed in advance and carefully reassessed along the way to
ensure that targets for study initiation were met. Presubmission
dialogue with ECs was critical to ensure that the timing and the
format of the research proposals were acceptable.
The preferred strategy was to submit to the sponsor ECs ﬁrst
whenever possible (PATH-REC or WIRB), then integrate their
comments into a new proposal, which would then be submitted
to the investigator ECs and to the WHO-ERC simultaneously.
For multisite studies, the proposals were usually submitted in
parallel to ECs of different investigator sites. Sponsor ECs
would, however, not grant ﬁnal approval until approvals from
all investigator ECs had been granted. After all EC approvals
were obtained, NRA submissions were made.
PATH institutional review board reviewers acted as a primary
ﬁlter before releasing the proposals to the WHO-ERC and
country site ECs. Tracked amendment forms enabled ECs of
sponsor and different investigator sites to have access to changes
Figure 1. Sponsor and site ethics committees in the Phase 2 and Phase 3 clinical development of the group A meningococcal conjugate vaccine (PsA-TT).
Abbreviation: WHO, World Health Organization.
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and their rationale, following the preceding reviews, and sup-
ported the sustained dialogue between all parties. This stepwise
approach and continuous interchange led to a more efﬁcient re-
view, with fewer revisions to study documents and fewer
resubmissions.
Postsubmission Dialogue
After each review, the sponsors (PATH and SIIL), together with
investigators, maintained a dialogue with the ECs, especially
when there were comments or questions. It was essential that
each comment and its implications were clearly understood by
all parties so that responses clearly addressed all questions. Fol-
low-up communication by email and telephonewas very valuable,
in particular, when a new collaboration with an EC was begun.
COMMUNITY PERMISSION
The success of any clinical study is largely dependent on com-
munity and participant support. The importance of community
involvement in international clinical trials has become increas-
ingly recognized [5–8].
Beyond obtaining the formal approvals from regulatory, eth-
ical, and scientiﬁc authorities, it was essential to solicit the active
support of the communities in India and West Africa where the
studies were taking place. In these traditional societies, particu-
larly in rural areas, community voices included the community
elders, religious leaders, elected councils, women’s associations,
traditional doctors, and local criers.
Initial community meetings prepared by the study investiga-
tors in collaboration with partners established a format for dia-
logue between the research team and the population, which was
maintained throughout the study. The research staff, investiga-
tors, and ﬁeldworkers, who often belonged to these communities,
played a critical role in keeping the communities engaged [5].
Once studies were completed, the results were shared with the
community through community feedback/dissemination meet-
ings. At these meetings, investigators presented the results of the
study. These meetings gave an opportunity for the study team to
address questions and provide recommendations based on ﬁnd-
ings and to thank the community and the participants for their
contributions. The feedback meetings also helped assure commu-
nity ownership and the possibility of future collaborations [5].
INFORMED CONSENT
As per the Declaration of Helsinki, ICH-GCP, and the regula-
tory guidelines, informed consent is critical to ensure the pro-
tection and the rights of potential research participants who
come into contact with the research team. In MVP studies, in-
formed consent was taken from all the participants ≥18 years of
age. For children and adolescents (1–17 years), parents/legal
guardians gave the consent. In addition, written assent was
taken from the participants for older children aged 12–17
years, following the local EC recommendations. When dealing
with illiterate participants/parents/legal guardians, an impartial
literate witness, independent from the investigator team, attest-
ed the consent process.
Translation to the Local Languages
Original informed consent forms were drafted and reviewed in
English; once ﬁnalized, appropriate translations were prepared
at speciﬁc sites. For Mali and Senegal, French translations were
developed. In India, translations in the Hindi, Marathi, Urdu,
and Telugu languages were developed. These translations were
back-translated to English and validated following a standard
operating procedure (SOP) before being submitted to ECs.
This validation process ensured that the translations were
done correctly.
In the early stages of the project, the same process was followed
to obtain formal translations and back-translations of the in-
formed consent forms in the local dialects of West Africa (par-
ticularly in Mali, Senegal, The Gambia, and Ghana). Consent
forms were prepared in the following local languages: Bambara,
Fula, Wollof, Mandinka, Sarahule, Nankam, Kassem, and Serer.
However, the local dialect translations posed 2 important
difﬁculties:
• The local dialects are verbal languages and not commonly
used in writing. Few people study their written form. The par-
ticipants and the study teams felt more comfortable in using the
forms in the ofﬁcial language of their country (French in Mali
and in Senegal; English in The Gambia and in Ghana) rather
than those in local dialects.
• The back-translation posed a signiﬁcant challenge because
the local dialects have different roots from Western languages.
Translators had to rely on the use of metaphors and cultural ref-
erences to translate Western vocabulary into the local dialects.
Such constructions had the potential to lose their meaning in
the back-translation, which posed greater challenges.
Due to the constraints surrounding writing of local dialects,
study sites used the following alternative approach (reviewed and
approved by ECs) to ensure the consent in the local languages.
Informed Consent as an Interactive Process
West African oral traditions rely heavily on the value of spoken
communication. “You have my word” is perceived as a more
powerful statement than a written signature. Participants ex-
pected some form of interaction and discussion to be able to as-
certain implications of their participation in the study.
Therefore, site teams used several methods and materials to
make the process easily understandable in the local dialects.
Teams developed tape recordings, transcripts of recordings in
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oral language, and speciﬁc trainings for study staff to convey in a
consistent manner consent information in the local languages.
Training sessions were documented; recordings and transcripts
were certiﬁed, reviewed, and approved by the local EC, although
these were not the literal translations of English forms.
Fieldworkers were fully trained on how to communicate the
elements of consent. An impartial literate witness ensured that
an oral communication matched information present in the
consent form.
After verbal discussion in the ﬁeld, the research team shared
copies of the informed consent forms (in English or French)
with potential participants and their families. In some sites,
during a ﬁrst visit to the clinic, potential participants were
given the opportunity to consult with their family and literate
relatives before making a decision.
During later studies, to ensure a good understanding of the
information provided prior to consenting, some of the study
sites began using assessment of understanding tools to evaluate
the comprehension of the study by the potential participant
prior to consent. This allowed the research team to revisit the
study information with the participant in case some aspects
had not been well understood.
Investigators and their research teams ensured a sound
approach for informed consent process using the above-
mentioned process. Such elements have emerged in the litera-
ture as proven approaches for the process of informed consent
[6, 7, 9, 10]. The success of the informed consent process still
required the investigators’ continued transparency, conﬁdenti-
ality, and respect of the participant in the implementation of
these tools, while ensuring a thorough documentation of each
informed consent.
PRACTICAL ISSUES
The following are some special situations that arose during the
trials.
Pregnancy Testing at Study Entry
From 2009 to 2011, at the Center for Vaccine Development, Ba-
mako, Mali, MVP conducted a large phase 3 study in the
healthy population aged 1–29 years. The study required a spe-
ciﬁc exclusion criterion to prevent the enrollment of pregnant
women. To comply, the study procedures included a negative
pregnancy test before vaccination for all women of childbearing
potential (ie, postmenarcheal and/or married women).
Initially, the protocol was reviewed by the WHO-ERC, which
requested precision on how to identify postmenarcheal women,
how assent would be done for minors, and what would ensue in
case of positive pregnancy test results in minors. The WHO-
ERC comments raised some challenging ethical questions to
the research team: How to request a pregnancy test from minors
and unmarried women? How to ensure the conﬁdentiality of
the test result in this group? How to manage the social conse-
quences of the positive test result for the participant and her
family? How to ensure that the process of pregnancy testing/
counseling is well accepted by the community?
These questions led to detailed exchanges between the local
EC, the WHO-ERC, the investigators, and the MVP responsible
medical ofﬁcer. The following approach satisﬁed the WHO-ERC
and the site EC and was culturally acceptable within the Malian
community context: An SOP for pregnancy testing was devel-
oped by the study site that deﬁned the informed consent process
and enrollment for women aged ≥18 years, for women aged 13–
17 years, and for girls aged 10–12 years. In each of these age
groups, a different approach was taken to ensure the conﬁdenti-
ality and respect of the potential participant. A counseling ofﬁce
was established to meet privately all women and young girls en-
tering the study. Following the SOP, trained midwives consulted
privately with the minor girl/woman about the need for a preg-
nancy test to enter the study and whether they would bewilling to
take the test. The decision to accept or refuse the test was kept
entirely conﬁdential. The strategy proved to be successful. The
discretion offered by the midwife counseling was well accepted
by the community and helped assure participation of minors in
the study. Over time, the midwife consultation became a popular
demand among the community.
This was an important lesson on how best to address an ethical
issue raised by a deﬁned research protocol. By working openly and
collectively with all parties, the issue was successfully resolved.
Provision of Care
A clinical study involves health assessment of the participants at
periodic clinical visits. During the assessments, health problems
unrelated to the study may be uncovered. In such cases, the
common practice is to provide medical referrals under the as-
sumption that participants will be able to obtain care using
their medical insurance coverage or from the public health sys-
tem, or last, will pay medical costs. The provision of ancillary
care in clinical trials has become an important issue in interna-
tional clinical research because access to healthcare varies con-
siderably from country to country [7, 11–13].
Some of our sites had governmental healthcare plans and
others had community pharmacies or charity clinics that pro-
vide basic care. However, the care provided at such different
sites may not be optimal and could put study participants at
risk. Though not a legal requirement, the sponsors considered
it a moral obligation to provide care and treatment to the par-
ticipants even in case of unrelated issues, in compliance with the
guidance principles provided in international ethical guidelines
[2, 3, 14, 15]. To ensure uniform medical care, for any related or
unrelated acute health issue diagnosed during the study, imme-
diate treatment was provided free of charge to every participant
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as per standard of care in the country. Investigators would work
closely with the local healthcare providers to ensure adequate
reimbursement of costs for participants, including purchasing
family health insurance for trial participants when available in
the participating community.
As the number of trials and the number of participants in-
creased over time, the investigators were confronted with a few
serious illnesses in study participants. Examples included a sub-
ject diagnosed with leukemia; a participant becoming paraplegic
after a tree fall; and a diagnosis of human immunodeﬁciency virus
infection. For each of these cases, the sponsor covered the cost of
any treatment and rehabilitation for the duration of the study. At
the end of the study, the sponsor worked with the investigators to
facilitate adequate referral, long-term support, and any follow-up.
The investigators were also confronted during the course of
our studies with broader health signals. In Ghana, for example,
a signiﬁcant number of malaria cases were encountered in the
study population. Across Ghana, Mali, and The Gambia, the in-
vestigators were faced with cases of serious malnutrition, often
related to harvest/climatic conditions and/or political instabili-
ty. This led the sponsor and the concerned site investigators to
take action for the subjects and the communities affected. This
is described in more detail elsewhere in this supplement [5].
All of the above examples illustrate how research teams and
sponsors of clinical studies can be confronted with medical is-
sues that extend beyond the traditional role of a researcher or a
sponsor but require attention.
Posttrial Access
Because our trials involved the administration of a study vaccine
(PsA-TT, MenAfriVac), we could not guarantee beneﬁt from any
protection against meningitis A after receipt of the investigational
vaccine. Therefore, we planned to offer a dose of the licensed
polysaccharide vaccine to subjects at the end of the studies.
However, when the immunogenicity and safety proﬁle of the
study vaccine became further characterized after the release of the
phase 2/3 trial results, 4 weeks after immunization, the study vac-
cine was found to perform better than the licensed vaccine, trig-
gering the MVP Expert Panel to recommend that the PsA-TT
conjugate vaccine be offered to all participants who had not re-
ceived it during the trial to be protected against meningitis
A. This recommendation posed a critical challenge; favorable
preliminary results from clinical trials were available, yet this vac-
cine had not reached a reasonably sized safety database and its
regulatory ﬁle was not yet ready for licensure submission.
Nevertheless, we decided to proceed with this recommenda-
tion by amending all relevant study protocols. At the end of the
original study, subjects with low immunogenicity responses
were offered the possibility to receive either a dose of the li-
censed ACWY polysaccharide vaccine or a dose of PsA-TT vac-
cine and be followed for an additional 3 months to monitor safety
parameters. This approach was accepted by the Project Advisory
Group and approved by all concerned ECs. There were, however,
logistical and timeline implications, and considerable additional
resources were needed to proceed with all ethical and regulatory
clearances as well as to support adequate ﬁeld implementation.
Nevertheless, our trials were taking place in areas where epidemic
meningitis caused by group A was a major health risk, and the
risk–beneﬁt ratio had become highly favorable to promote its ac-
cess to study participants in compliance with the guiding princi-
ples of international ethical guidelines [16].
For later trials, the PsA-TT conjugate vaccine was fully
licensed for the 1- to 29-year-olds. By the time these later trials
drew to a close, we could offer the PsA-TT outside study proce-
dures to all subjects within this age category without any partic-
ular safety follow-up. In addition, in the following years, all
countries where clinical trials were implemented introduced
the vaccine through national campaigns, which provided cover-
age to all communities who participated in the trials.
This issue of timely access of participating communities to an
investigational product is a common concern in international
clinical trials [8, 11] and was raised during the MVP develop-
ment. Our response was probably imperfect and raised additional
logistical challenges. However, it does illustrate the need to devel-
op approaches early in study plans for posttrial access that is rea-
sonable to the communities and in line with sponsor resources
without compromising safety and scientiﬁc objectives.
CONCLUSIONS
The diverse cultures encompassed in the study sites meant that
a regional ethical approach could not necessarily work in the
same manner in each site. Hence, alternative approaches were
developed to respect the social and cultural context of the com-
munity. Respect, listening, and working collectively were all
equally important to make things happen. Building from past
experiences across cultures, the investigators and the sponsors
were sensitive to these aspects from the start. When different
parties had differing beliefs about the right way to deal with a
situation, discussion and exchanges were essential to under-
stand one another’s point of view. With patience and dialogue,
a common ground could be built to develop research proposals.
The ﬁeld of ethics in international clinical trials is a dynamic
environment. The experiences that are faced in the ﬁeld continue
to inform levels of regulatory and ethical scrutiny. During 8 years
of MVP clinical trials, we sensed an increased demand for
real ﬁeld questions. While collaborating with diverse ethics
committees, we beneﬁted from complementary perspectives
as well as the experience of navigating through multiple review
processes in a continuous, mutually enriching dialogue to the
beneﬁt of the quality of research and attention to participating
communities. Investigators and sponsors accumulated experiences
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and challenges that proved to be of interest to ECs, advisory com-
mittees, and independent safety monitoring boards. We shared
our experiences on the informed consent process, community
and participant healthcare, disease prevention, aspects of counsel-
ing, and conﬁdentiality within diverse cultural settings, in an effort
to enrich the ethical context of the MVP trials.
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